If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> HEPATOLOGY<br /> EMJ Hepatol. 2018 Suppl 1 • europeanmedical-journal.com<br /> INSIDE<br /> Primary Biliary Cholangitis<br /> in Motion Meeting<br /> Primary Biliary Cholangitis in Motion Meeting<br /> The PBC in Motion meeting took place<br /> on 10th March 2018 in Heathrow, UK<br /> Chair People: Dave Jones,1 Luigi Muratori2<br /> Speakers: Achim Kautz,3 Gideon Hirschfield,4 Jörg Petersen,5 Andreas Kremer,6<br /> Dave Jones,1 Laurent Castera,7 Ulrich Beuers,8 Cecília M.P. Rodrigues,9<br /> Frederik Nevens,10 Vincent Leroy11<br /> 1. Institute of Cellular Medicine, Newcastle University, Newcastle, UK<br /> 2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy<br /> 3. Patient group representative, European PBC Network, Düsseldorf, Germany<br /> 4. Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK<br<a title="EMJ Hepatol. 2018 Suppl 1 page 1" href="http://viewer.zmags.com/publication/a526ca78?page=1"> HEPATOLOGY EMJ Hepatol. 2018 Suppl 1 • europeanme</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 2" href="http://viewer.zmags.com/publication/a526ca78?page=2"> Primary Biliary Cholangitis in Motion Meeting Th</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 3" href="http://viewer.zmags.com/publication/a526ca78?page=3"> Pharmaceuticals and has received research fundin</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 4" href="http://viewer.zmags.com/publication/a526ca78?page=4"> burden that can leave patients fee</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 5" href="http://viewer.zmags.com/publication/a526ca78?page=5"> Ursodeoxycholic Acid Oral UDCA (13–15 mg/kg/day) </a> <a title="EMJ Hepatol. 2018 Suppl 1 page 6" href="http://viewer.zmags.com/publication/a526ca78?page=6"> Responders 1.0 0.9 Survival without adverse ou</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 7" href="http://viewer.zmags.com/publication/a526ca78?page=7"> A second-line treatment option for pruritus is ri</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 8" href="http://viewer.zmags.com/publication/a526ca78?page=8"> Serum biomarker tests have good reproducibility, </a> <a title="EMJ Hepatol. 2018 Suppl 1 page 9" href="http://viewer.zmags.com/publication/a526ca78?page=9"> reduction of bile toxicity, and antiapoptoti</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 10" href="http://viewer.zmags.com/publication/a526ca78?page=10"> ≥1.67-fold the ULN and/or total bilirubin greater</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 11" href="http://viewer.zmags.com/publication/a526ca78?page=11"> A ALP Doub</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 12" href="http://viewer.zmags.com/publication/a526ca78?page=12"> PATIENT MANAGEMENT OBETICHOLIC ACID: REAL-WORLD </a> <a title="EMJ Hepatol. 2018 Suppl 1 page 13" href="http://viewer.zmags.com/publication/a526ca78?page=13"> showed that these results were sustained, and ALP</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 14" href="http://viewer.zmags.com/publication/a526ca78?page=14"> 2014;60(1):399-407. 12. Hegade VS et al. A syst</a> <a title="EMJ Hepatol. 2018 Suppl 1 page 15" href="http://viewer.zmags.com/publication/a526ca78?page=15"> Abbreviated Prescribing Information OCALIVA® (ob</a>